Venatorx Pharmaceuticals Inc.

Venatorx Pharmaceuticals Inc., doing business as Venatorx, is a biopharmaceutical company specializing in the discovery and development of novel anti-infective therapeutics. The company focuses on addressing urgent global health threats, particularly antibiotic-resistant bacteria and viral infections. Through federal contract and grant awards, Venatorx provides research and development services to the U.S. government, primarily in the areas of new antibiotics, antivirals, and medical countermeasures against chemical, biological, radiological, and nuclear threats. Venatorx leverages its expertise in medicinal chemistry, microbiology, and drug development to advance innovative treatments for challenging infectious diseases.

Venatorx has been awarded several substantial federal contracts, primarily from the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) and the National Institute of Allergy and Infectious Diseases (NIAID). These contracts, ranging from $44 million to $318 million, support the development of novel antibiotics and medical countermeasures. Key projects include the advancement of new antibiotics to treat drug-resistant gram-negative bacteria, including public health pathogens, and the development of an antibiotic for biothreat pathogens such as Yersinia pestis, Francilla tularensis, and Burkholderia pseudomallei. The company's work also extends to creating a novel beta-lactamase inhibitor targeting multidrug-resistant Acinetobacter baumannii. These contracts are typically cost-sharing or cost-plus-fixed-fee arrangements, reflecting the high-risk, high-reward nature of advanced pharmaceutical research. Notably, none of Venatorx's federal contracts have set-aside designations, indicating they compete in full and open competition.

In the realm of federal grants, Venatorx has received numerous awards from NIAID under various research programs, including Allergy and Infectious Diseases Research (CFDA 93.855). These grants, typically in the form of Project Grants, support a wide range of research initiatives. Key projects include the development of novel cyclic boronate cell wall inhibitors targeting carbapenem-resistant Acinetobacter baumannii, the discovery of antiviral inhibitors for orthopoxvirus infections (including smallpox), and the optimization of orally bioavailable inhibitors for COVID-19 and other human coronavirus infections. Other significant grant-funded work includes the preclinical development of capsid assembly modulators for chronic hepatitis B virus infection, the creation of broad-spectrum β-lactamase inhibitors for multidrug-resistant Pseudomonas aeruginosa, and the discovery of inhibitors targeting HBx for chronic HBV infection. Venatorx has also received subgrants, with partners such as the Trustees of Boston University, to develop new oral antibiotic options for gonorrhea, addressing the urgent need for treatments against resistant strains.